Walleye Capital LLC Makes New $180,000 Investment in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Walleye Capital LLC has made a new investment of approximately $180,000 in Eyepoint Pharmaceuticals, acquiring 33,206 shares of the company.
• Eyepoint Pharmaceuticals has seen significant changes in institutional ownership, with multiple hedge funds increasing their stakes, resulting in over 99.41% of the company's stock being held by institutional investors.
• The company recently reported earnings of ($0.85) per share, missing analyst estimates, and has an average target price of $26.86 from analysts, indicating a consensus "Buy" rating.

Walleye Capital LLC bought a new stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,206 shares of the company's stock, valued at approximately $180,000.

Other hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in shares of Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $76,000. GAMMA Investing LLC raised its holdings in shares of Eyepoint Pharmaceuticals by 3,174.4% during the first quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after acquiring an additional 9,936 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $91,000. Arizona State Retirement System raised its holdings in shares of Eyepoint Pharmaceuticals by 12.7% during the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after acquiring an additional 1,877 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in shares of Eyepoint Pharmaceuticals by 208.8% during the first quarter. New York State Common Retirement Fund now owns 20,114 shares of the company's stock valued at $109,000 after acquiring an additional 13,600 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

Analyst Upgrades and Downgrades

EYPT has been the subject of a number of research analyst reports. Royal Bank Of Canada started coverage on Eyepoint Pharmaceuticals in a report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 target price for the company. HC Wainwright increased their price target on Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Mizuho cut their price target on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a report on Friday, May 16th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a report on Thursday, August 7th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $26.86.

Eyepoint Pharmaceuticals Stock Down 1.0%

EYPT opened at $11.88 on Friday. Eyepoint Pharmaceuticals, Inc. has a 52 week low of $3.91 and a 52 week high of $13.98. The business has a fifty day simple moving average of $10.63 and a 200-day simple moving average of $8.00. The firm has a market cap of $818.89 million, a P/E ratio of -4.43 and a beta of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). The company had revenue of $5.33 million during the quarter, compared to analysts' expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. Sell-side analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.